(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.18%
@ $1.778
发出时间: 14 Feb 2024 @ 22:30
回报率: 15.29%
上一信号: Feb 13 - 03:27
上一信号:
回报率: -3.36 %
Live Chart Being Loaded With Signals
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders...
Stats | |
---|---|
今日成交量 | 1.17M |
平均成交量 | 1.60M |
市值 | 343.20M |
EPS | $0 ( 2024-03-29 ) |
下一个收益日期 | ( $-0.200 ) 2024-05-09 |
Last Dividend | $6.00 ( 2018-08-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.20 |
ATR14 | $0.00300 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Apeiron Investment Group Ltd. | Buy | 147 950 | Convertible Notes |
2024-04-15 | Apeiron Investment Group Ltd. | Sell | 147 950 | Convertible Notes |
2024-04-02 | Johnson Anne Nagengast | Sell | 27 410 | Common Shares |
2024-04-02 | Rao Srinivas | Sell | 61 640 | Common Shares |
2024-04-02 | Kirpekar Sahil | Sell | 35 801 | Common Shares |
INSIDER POWER |
---|
56.53 |
Last 90 transactions |
Buy: 18 737 833 | Sell: 13 770 797 |
音量 相关性
ATA Inc. 相关性 - 货币/商品
ATA Inc. 财务报表
Annual | 2023 |
营收: | $314 000 |
毛利润: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2023 |
营收: | $314 000 |
毛利润: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2022 |
营收: | $233 000 |
毛利润: | $65 000.00 (27.90 %) |
EPS: | $-0.910 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
ATA Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.430 | 2011-06-28 |
Last Dividend | $6.00 | 2018-08-27 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $7.36 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.25 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -128.70 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.138 | 1.200 | -4.59 | -5.51 | [0 - 0.3] |
returnOnEquityTTM | -0.920 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.24 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0528 | -1.500 | 9.12 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -46.97 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.524 | 2.00 | -0.175 | -0.349 | [0 - 30] |
freeCashFlowPerShareTTM | -0.528 | 2.00 | -0.264 | -0.528 | [0 - 20] |
debtEquityRatioTTM | 0.0637 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.710 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.42 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.38 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00107 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | -2.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -8.06 | 1.000 | -0.915 | 0 | [1 - 100] |
returnOnEquityTTM | -0.920 | 2.50 | -7.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.528 | 2.00 | -0.176 | -0.528 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.524 | 2.00 | -0.175 | -0.349 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0846 | 1.500 | -3.90 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -265.15 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.75 |
ATA Inc.
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。